Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Ending the HIV Epidemic: Keys to Successful Treatment Initiation

Listen to Chloe Orkin, MBChB, FRCP, MD, discuss why HIV treatment initiation is such a crucial part of putting an end to HIV, and hear patient perspectives on the difference that rapid ART initiation can make on a personal level.
Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD
Nagalingeswaran Kumarasamy, MBBS, FRCP, PhD
Chloe Orkin Photo
Chloe Orkin, MBChB, FRCP, MD
Babafemi Taiwo, MBBS
Released: August 24, 2022

In this episode, Chloe Orkin, MBChB, FRCP, MD, discusses strategies for successful antiretroviral therapy (ART) initiation. Her overview includes:

  • Recommendations for rapid ART
  • First-line ART regimens for treatment-naive people with HIV
  • IMEA 055 FAST study
  • STAT study
  • DIAMOND study
  • Antiretroviral resistance mutations
  • Patient perspectives on the importance of rapid ART initiation

Information on this Educational Activity

Faculty

Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD

Director
Desmond Tutu HIV Centre
Past President
International AIDS Society
Faculty of Health Sciences
University of Cape Town,
Cape Town, South Africa

Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD: consultant/advisor/speaker: Cepheid, Gilead Sciences, Janssen (J&J), Merck (MSD), ViiV Healthcare.
Nagalingeswaran Kumarasamy, MBBS, FRCP, PhD

Chief & Director
VHS-Infectious Diseases Medical Centre
Director
Chennai Antiviral Research and Treatment (CART) Clinical Research Site
Voluntary Health Services
Chennai, India

Nagalingeswaran Kumarasamy, MBBS, FRCP, PhD, has no relevant financial relationships to disclose.
Chloe Orkin, MBChB, FRCP, MD

Professor of HIV
Queen Mary, University of London
Consultant Physician
Lead for HIV Research
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom

Chloe Orkin, MBChB, FRCP, MD: consultant/advisor/speaker: Gilead Sciences, Janssen, MSD, ViiV Healthcare; researcher: Gilead Sciences, Janssen, MSD, ViiV Healthcare.
Babafemi Taiwo, MBBS

Gene Stollerman Professor of Medicine
Chief,
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Babafemi Taiwo, MBBS: consultant/advisor/speaker: Gilead Sciences, GlaxoSmithKline, Johnson and Johnson, ViiV Healthcare.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Gilead Sciences, Inc.

Related Content

Discussion of barriers and calls to action for providing patient-centered HIV care in Malaysia from a healthcare professional and a patient advocate, from Clinical Care Options (CCO)

person default Iskandar Azwa, MBChB Andrew Tan Released: December 7, 2022

Dr Monica Gandhi discusses key advances in HIV treatment over the past year, from Clinical Care Options (CCO)

Monica Gandhi, MD, MPH Released: December 2, 2022

A patient advocate discusses the importance of community-led HIV treatment and prevention, from Clinical Care Options (CCO)

person default Rena Janamnuaysook, MBA Released: December 2, 2022

Review the latest data on ART safety and tolerability in special populations in this slideset, from Clinical Care Options (CCO)

Jean Rene Anderson, MD Jill Blumenthal, MD, MAS Marta Boffito, MD, PhD, FRCP Jennifer Cocohoba Headshot Jennifer Cocohoba, PharmD Joseph J. Eron, Jr., MD Julian Falutz, MD, FRCPC Eric K. Farmer, PharmD, BCPS, AAHIVP Priscilla Y. Hsue, MD Jens D. Lundgren, MD, DMSc William R. Short, MD, MPH, AAHIVS Darcy Wooten, MD Released: November 28, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings